vs

Side-by-side financial comparison of MACROGENICS INC (MGNX) and FiscalNote Holdings, Inc. (NOTE). Click either name above to swap in a different company.

MACROGENICS INC is the larger business by last-quarter revenue ($41.2M vs $22.2M, roughly 1.9× FiscalNote Holdings, Inc.). On growth, MACROGENICS INC posted the faster year-over-year revenue change (113.0% vs -24.7%). MACROGENICS INC produced more free cash flow last quarter ($42.8M vs $-1.9M). Over the past eight quarters, MACROGENICS INC's revenue compounded faster (112.8% CAGR vs -16.8%).

MacroGenics Inc is a clinical-stage biopharmaceutical firm specializing in the research and development of novel immunotherapies for cancer and autoimmune disorders. Its core product pipeline centers on monoclonal antibody-based treatments, with key programs targeting solid tumors and hematological malignancies, supported by partnerships with global pharmaceutical partners.

FiscalNote Holdings, Inc., or commonly FiscalNote, is a publicly traded software, data, and media company headquartered in Washington, D.C. The company was founded by Timothy Hwang, Gerald Yao, and Jonathan Chen in 2013. FiscalNote provides software tools, platforms, data services, and news through the FiscalNote Government Relationship Management (GRM) service, its core product. The company also uses an artificial intelligence platform to analyze proposed U.S. legislation based on key phrase...

MGNX vs NOTE — Head-to-Head

Bigger by revenue
MGNX
MGNX
1.9× larger
MGNX
$41.2M
$22.2M
NOTE
Growing faster (revenue YoY)
MGNX
MGNX
+137.7% gap
MGNX
113.0%
-24.7%
NOTE
More free cash flow
MGNX
MGNX
$44.7M more FCF
MGNX
$42.8M
$-1.9M
NOTE
Faster 2-yr revenue CAGR
MGNX
MGNX
Annualised
MGNX
112.8%
-16.8%
NOTE

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
MGNX
MGNX
NOTE
NOTE
Revenue
$41.2M
$22.2M
Net Profit
Gross Margin
Operating Margin
-29.3%
-83.7%
Net Margin
Revenue YoY
113.0%
-24.7%
Net Profit YoY
EPS (diluted)
$-0.23
$-2.81

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
MGNX
MGNX
NOTE
NOTE
Q4 25
$41.2M
$22.2M
Q3 25
$72.8M
$22.4M
Q2 25
$22.2M
$23.3M
Q1 25
$13.2M
$27.5M
Q4 24
$19.4M
$29.5M
Q3 24
$110.7M
$29.4M
Q2 24
$10.8M
$29.2M
Q1 24
$9.1M
$32.1M
Net Profit
MGNX
MGNX
NOTE
NOTE
Q4 25
Q3 25
$16.8M
$-24.9M
Q2 25
$-36.3M
$-13.3M
Q1 25
$-41.0M
$-4.3M
Q4 24
Q3 24
$56.3M
$-14.9M
Q2 24
$-55.7M
$-12.8M
Q1 24
$-52.2M
$50.6M
Gross Margin
MGNX
MGNX
NOTE
NOTE
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
98.8%
Q3 24
99.8%
Q2 24
98.4%
Q1 24
97.0%
Operating Margin
MGNX
MGNX
NOTE
NOTE
Q4 25
-29.3%
-83.7%
Q3 25
25.6%
-43.4%
Q2 25
-165.3%
-31.9%
Q1 25
-323.1%
-50.0%
Q4 24
-273.0%
-19.4%
Q3 24
48.9%
-23.1%
Q2 24
-538.9%
-27.2%
Q1 24
-590.4%
-35.6%
Net Margin
MGNX
MGNX
NOTE
NOTE
Q4 25
Q3 25
23.1%
-110.8%
Q2 25
-163.0%
-57.0%
Q1 25
-311.1%
-15.4%
Q4 24
Q3 24
50.9%
-50.7%
Q2 24
-515.6%
-43.6%
Q1 24
-573.3%
157.6%
EPS (diluted)
MGNX
MGNX
NOTE
NOTE
Q4 25
$-0.23
$-2.81
Q3 25
$0.27
$-1.73
Q2 25
$-0.57
$-0.08
Q1 25
$-0.65
$-0.03
Q4 24
$-0.24
$1.88
Q3 24
$0.90
$-1.33
Q2 24
$-0.89
$-0.09
Q1 24
$-0.84
$0.37

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
MGNX
MGNX
NOTE
NOTE
Cash + ST InvestmentsLiquidity on hand
$57.2M
$26.3M
Total DebtLower is stronger
$128.4M
Stockholders' EquityBook value
$55.6M
$62.0M
Total Assets
$256.8M
$255.1M
Debt / EquityLower = less leverage
2.07×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
MGNX
MGNX
NOTE
NOTE
Q4 25
$57.2M
$26.3M
Q3 25
$80.1M
$31.2M
Q2 25
$130.7M
$38.5M
Q1 25
$145.6M
$46.3M
Q4 24
$182.8M
$34.6M
Q3 24
$179.6M
$32.7M
Q2 24
$83.9M
$37.7M
Q1 24
$80.4M
$43.6M
Total Debt
MGNX
MGNX
NOTE
NOTE
Q4 25
$128.4M
Q3 25
$131.5M
Q2 25
$116.7M
Q1 25
$118.0M
Q4 24
$147.1M
Q3 24
$152.2M
Q2 24
$145.9M
Q1 24
$153.0M
Stockholders' Equity
MGNX
MGNX
NOTE
NOTE
Q4 25
$55.6M
$62.0M
Q3 25
$67.0M
$75.5M
Q2 25
$46.6M
$95.1M
Q1 25
$79.1M
$98.7M
Q4 24
$116.1M
$97.8M
Q3 24
$120.1M
$98.5M
Q2 24
$57.8M
$106.9M
Q1 24
$106.2M
$106.1M
Total Assets
MGNX
MGNX
NOTE
NOTE
Q4 25
$256.8M
$255.1M
Q3 25
$270.8M
$273.9M
Q2 25
$245.4M
$288.3M
Q1 25
$224.6M
$299.7M
Q4 24
$261.7M
$326.2M
Q3 24
$264.5M
$337.9M
Q2 24
$201.1M
$346.3M
Q1 24
$248.3M
$357.8M
Debt / Equity
MGNX
MGNX
NOTE
NOTE
Q4 25
2.07×
Q3 25
1.74×
Q2 25
1.23×
Q1 25
1.20×
Q4 24
1.50×
Q3 24
1.54×
Q2 24
1.36×
Q1 24
1.44×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
MGNX
MGNX
NOTE
NOTE
Operating Cash FlowLast quarter
$43.0M
$-279.0K
Free Cash FlowOCF − Capex
$42.8M
$-1.9M
FCF MarginFCF / Revenue
103.8%
-8.7%
Capex IntensityCapex / Revenue
0.6%
7.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-83.0M
$-18.6M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
MGNX
MGNX
NOTE
NOTE
Q4 25
$43.0M
$-279.0K
Q3 25
$-30.2M
$-8.3M
Q2 25
$-47.0M
$-6.2M
Q1 25
$-46.9M
$3.3M
Q4 24
$-38.4M
$-1.3M
Q3 24
$60.2M
$-3.0M
Q2 24
$-44.5M
$-3.7M
Q1 24
$-45.6M
$2.7M
Free Cash Flow
MGNX
MGNX
NOTE
NOTE
Q4 25
$42.8M
$-1.9M
Q3 25
$-30.6M
$-10.4M
Q2 25
$-47.7M
$-7.7M
Q1 25
$-47.4M
$1.3M
Q4 24
$-39.0M
$-3.4M
Q3 24
$59.6M
$-5.4M
Q2 24
$-45.5M
$-6.5M
Q1 24
$-47.1M
$1.0M
FCF Margin
MGNX
MGNX
NOTE
NOTE
Q4 25
103.8%
-8.7%
Q3 25
-42.0%
-46.2%
Q2 25
-214.5%
-33.0%
Q1 25
-359.5%
4.7%
Q4 24
-201.7%
-11.4%
Q3 24
53.8%
-18.4%
Q2 24
-421.6%
-22.1%
Q1 24
-517.4%
3.3%
Capex Intensity
MGNX
MGNX
NOTE
NOTE
Q4 25
0.6%
7.4%
Q3 25
0.6%
9.3%
Q2 25
3.2%
6.4%
Q1 25
4.0%
7.2%
Q4 24
3.2%
6.8%
Q3 24
0.5%
8.3%
Q2 24
9.6%
9.4%
Q1 24
16.0%
5.3%
Cash Conversion
MGNX
MGNX
NOTE
NOTE
Q4 25
Q3 25
-1.79×
Q2 25
Q1 25
Q4 24
Q3 24
1.07×
Q2 24
Q1 24
0.05×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

MGNX
MGNX

Revenue From Collaborative Agreements$20.3M49%
Contract Manufacturing$11.3M27%
Other$9.7M23%

NOTE
NOTE

Subscription$21.2M95%
Advisory Advertising And Other$1.0M5%

Related Comparisons